Mucosal vaccination against bacterial respiratory infections

References

• CDC. Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006–2015. MMWR Morb. Mortal. Wkly Rep.55(18), 511–515 (2006).
   PubMedGoogle Scholar
• Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet357(9261), 1008–1011 (2001).
   PubMed Web of Science ®Google Scholar
• CDC. Pneumococcal disease. In: Epidemiology and Prevention of Vaccine Preventable Diseases: The Pink Book. CDC (Ed.). GA, USA 257–270 (2007).
   Google Scholar
• CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep.54(36), 893–897 (2005).
   PubMedGoogle Scholar
• Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA297(16), 1784–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Maestro B, Sanz JM. Novel approaches to fight Streptococcus pneumoniae . Recent Patents Anti-Infect. Drug Disc.2(3), 188–196 (2007).
   PubMedGoogle Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med.344(6), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis.25(2), 90–97 (2006).
   PubMed Web of Science ®Google Scholar
• Pollabauer EM, Petermann R, Ehrlich HJ. Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum. Vaccin.1(4), 131–139 (2005).
   PubMed Web of Science ®Google Scholar
• CDC. Meningococcal disease. In: Epidemiology and Prevention of Vaccine Preventable Diseases: The Pink Book. CDC (Ed.), GA, USA 271–281 (2007)
   Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis : protection trial and mass vaccination results in Cuba. NIPH Ann.14(2), 195–207 (1991).
   PubMedGoogle Scholar
• Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338(8775), 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340(8827), 1074–1078 (1992).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Yero D, Pajon R, Perez Y et al. Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. Vaccine25(28), 5175–5188 (2007).
   PubMed Web of Science ®Google Scholar
• Bottero D, Gaillard ME, Fingermann M et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin. Vaccine Immunol.14(11), 1490–1498 (2007).
   PubMedGoogle Scholar
• CDC. Pertussis outbreak in an Amish community – Kent County, Delaware, September 2004–February 2005. MMWR Morb. Mortal. Wkly Rep.55(30), 817–821 (2006).
   PubMedGoogle Scholar
• Verhamme KM, De Coster W, De Roo L et al. Pathogens in early-onset and late-onset intensive care unit-acquired pneumonia. Infect. Control Hosp. Epidemiol.28(4), 389–397 (2007).
   PubMed Web of Science ®Google Scholar
• Rello J, Rodriguez A, Torres A et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur. Respir. J.27(6), 1210–1216 (2006).
   PubMed Web of Science ®Google Scholar
• Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Opin. Pulm. Med.12(6), 428–432 (2006).
   PubMed Web of Science ®Google Scholar
• Fajardo A, Martinez-Martin N, Mercadillo M et al. The neglected intrinsic resistome of bacterial pathogens. PLoS ONE3(2), e1619 (2008).
   PubMed Web of Science ®Google Scholar
• Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled Phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA104(26), 11020–11025 (2007).
   PubMed Web of Science ®Google Scholar
• Lang AB, Rudeberg A, Schoni MH et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr. Infect. Dis. J.23(6), 504–510 (2004).
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost–effectiveness. Lancet367(9517), 1173–1180 (2006).
   PubMed Web of Science ®Google Scholar
• Rodrigues A, Schellenberg JA, Roth A et al. Revaccination with Bacillus Calmette-Guerin (BCG) vaccine does not reduce morbidity from malaria in African children. Trop. Med. Int. Health12(2), 224–229 (2007).
   PubMedGoogle Scholar
• Brennan MJ, Fruth U, Milstien J et al. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med.4(8), e252 (2007).
   PubMed Web of Science ®Google Scholar
• Wiker HG, Mustafa T, Malen H, Riise AM. Vaccine approaches to prevent tuberculosis. Scand. J. Immunol.64(3), 243–250 (2006).
   PubMed Web of Science ®Google Scholar
• Plebani A, Soresina A, Rondelli R et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin. Immunol.104(3), 221–230 (2002).
   PubMed Web of Science ®Google Scholar
• Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin. Exp. Immunol.120(2), 225–231 (2000).
   PubMed Web of Science ®Google Scholar
• Carsetti R, Rosado MM, Donnanno S et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J. Allergy Clin. Immunol.115(2), 412–417 (2005).
   PubMed Web of Science ®Google Scholar
• Merrill WW, Naegel GP, Olchowski JJ, Reynolds HY. Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects. Quantitation and comparison with immunoglobulins A and E. Am. Rev. Respir. Dis.131(4), 584–587 (1985).
   PubMedGoogle Scholar
• Baumann U, Gocke K, Gewecke B, Freihorst J, von Specht BU. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa : a clinical Phase I/II study. Respir. Res.8, 57 (2007).
   PubMed Web of Science ®Google Scholar
• Baumann U, Schmidt RE, Gessner JE. New insights into the pathophysiology and in vivo function of IgG Fc receptors through gene deletion studies. Arch. Immunol. Ther. Exp. (Warsz.)51(6), 399–406 (2003).
   PubMed Web of Science ®Google Scholar
• Sjoholm AG, Jonsson G, Braconier JH, Sturfelt G, Truedsson L. Complement deficiency and disease: an update. Mol. Immunol.43(1–2), 78–85 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshida T, Usui A, Kusumi T et al. A quantitative analysis of cedar pollen-specific immunoglobulins in nasal lavage supported the local production of specific IgE, not of specific IgG. Microbiol. Immunol.49(6), 529–534 (2005).
   PubMed Web of Science ®Google Scholar
• Bellanti JA, Zeligs BJ, Mendez-Inocencio J et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine22(9–10), 1214–1220 (2004).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int. J. Med. Microbiol.293(1), 3–15 (2003).
   PubMed Web of Science ®Google Scholar
• Malley R, Srivastava A, Lipsitch M et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect. Immun.74(4), 2187–2195 (2006).
   PubMed Web of Science ®Google Scholar
• Trzcinski K, Thompson CM, Srivastava A et al. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect. Immun.76(6), 2678–2684 (2008).
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Butcher EC. Plasma-cell homing. Nat. Rev. Immunol.3(10), 822–829 (2003).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Johansen FE. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol. Rev.206, 32–63 (2005).
   PubMed Web of Science ®Google Scholar
• Heier I, Malmstrom K, Pelkonen AS et al. Bronchial response pattern of antigen presenting cells and regulatory T cells in children below two years of age. Thorax63(8), 703–709 (2008).
   PubMed Web of Science ®Google Scholar
• Quiding-Jabrink M, Nordstrom I, Granstrom G et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Invest.99(6), 1281–1286 (1997).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Claypool SM, Wagner JS et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity20(6), 769–783 (2004).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Halstensen TS, Kett K et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology97(6), 1562–1584 (1989).
   PubMed Web of Science ®Google Scholar
• Debertin AS, Tschernig T, Tonjes H et al. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin. Exp. Immunol.134(3), 503–507 (2003).
   PubMed Web of Science ®Google Scholar
• Turesson I. Distribution of immunoglobulin-containing cells in human bone marrow and lymphoid tissues. Acta Med. Scand.199(4), 293–304 (1976).
   PubMed Web of Science ®Google Scholar
• Gordon SB, Miller DE, Day RB et al. Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults. J. Infect. Dis.188(5), 666–670 (2003).
   PubMed Web of Science ®Google Scholar
• Mestecky J, Moldoveanu Z, Elson CO. Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine23(15), 1800–1803 (2005).
   PubMed Web of Science ®Google Scholar
• Oliveira ML, Areas AP, Ho PL. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev. Vaccines6(3), 419–429 (2007).
   PubMed Web of Science ®Google Scholar
• Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin. Drug Deliv.3(1), 87–95 (2006).
   PubMedGoogle Scholar
• Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med.338(20), 1405–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.356(7), 685–696 (2007).
   PubMed Web of Science ®Google Scholar
• Durrer P, Gluck U, Spyr C et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine21(27–28), 4328–4334 (2003).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Arnold H, Bumann D, Felies M et al. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa . Infect. Immun.72(11), 6546–6553 (2004).
   PubMed Web of Science ®Google Scholar
• Song JH, Nguyen HH, Cuburu N et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA105(5), 1644–1649 (2008).
   PubMed Web of Science ®Google Scholar
• Giri PK, Verma I, Khuller GK. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J. Infect.53(5), 350–356 (2006).
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Debrie AS, Raze D et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog.2(7), e65 (2006).
   PubMed Web of Science ®Google Scholar
• Locht C, Antoine R, Raze D et al.Bordetella pertussis from functional genomics to intranasal vaccination. Int. J. Med. Microbiol.293(7–8), 583–588 (2004).
   PubMed Web of Science ®Google Scholar
• Oliveira ML, Areas AP, Campos IB et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect.8(4), 1016–1024 (2006).
   PubMed Web of Science ®Google Scholar
• Huter V, Hensel A, Brand E, Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol.83(1–2), 161–172 (2000).
   PubMed Web of Science ®Google Scholar
• Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev. Vaccines6(2), 241–253 (2007).
   PubMed Web of Science ®Google Scholar
• van Roosmalen ML, Kanninga R, El Khattabi M et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods38(2), 144–149 (2006).
   PubMed Web of Science ®Google Scholar
• Duc le H, Hong HA, Atkins HS et al. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine25(2), 346–355 (2007).
   PubMed Web of Science ®Google Scholar
• Goonetilleke NP, McShane H, Hannan CM et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171(3), 1602–1609 (2003).
   PubMed Web of Science ®Google Scholar
• Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173(10), 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Akisada T, Harada T, Haruma K. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med. Mol. Morphol.39(4), 181–186 (2006).
   PubMed Web of Science ®Google Scholar
• de Jonge MI, Hamstra HJ, Jiskoot W et al. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine22(29–30), 4021–4028 (2004).
   PubMed Web of Science ®Google Scholar
• Kang ML, Jiang HL, Kang SG et al. Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine25(23), 4602–4610 (2007).
   PubMed Web of Science ®Google Scholar
• Baudner BC, Verhoef JC, Giuliani MM et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J. Drug Target13(8–9), 489–498 (2005).
   PubMed Web of Science ®Google Scholar
• Hou Y, Hu WG, Hirano T, Gu XX. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine20(17–18), 2375–2381 (2002).
   PubMed Web of Science ®Google Scholar
• Larbig M, Mansouri E, Freihorst J et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine19(17–19), 2291–2297 (2001).
   PubMed Web of Science ®Google Scholar
• DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect. Immun.72(12), 7012–7021 (2004).
   PubMed Web of Science ®Google Scholar
• Toth A, Schodel F, Duchene M et al. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella Dublin. Vaccine12(13), 1215–1221 (1994).
   PubMed Web of Science ®Google Scholar
• Xin W, Wanda SY, Li Y et al. Analysis of Type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect. Immun.76(7), 3241–3254 (2008).
   PubMed Web of Science ®Google Scholar
• Cheminay C, Hensel M. Rational design of Salmonella recombinant vaccines. Int. J. Med. Microbiol.298(1–2), 87–98 (2008).
   PubMedGoogle Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine23(15), 1804–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Fraser CK, Diener KR, Brown MP, Hayball JD. Improving vaccines by incorporating immunological coadjuvants. Expert Rev. Vaccines6(4), 559–578 (2007).
   PubMed Web of Science ®Google Scholar
• Sabirov A, Metzger DW. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine24(27–28), 5584–5592 (2006).
   PubMed Web of Science ®Google Scholar
• Sabirov A, Metzger DW. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine26(12), 1566–1576 (2008).
   PubMed Web of Science ®Google Scholar
• Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun.71(8), 4780–4788 (2003).
   PubMed Web of Science ®Google Scholar
• Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae . J. Infect. Dis.175(4), 839–846 (1997).
   PubMed Web of Science ®Google Scholar
• Tanaka N, Fukuyama S, Fukuiwa T et al. Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice. Vaccine25(14), 2680–2687 (2007).
   PubMed Web of Science ®Google Scholar
• Hirano T, Jiao X, Chen Z, Van Waes C, Gu XX. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol. Lett.107(2), 131–139 (2006).
   PubMed Web of Science ®Google Scholar
• Abe N, Kodama S, Hirano T, Eto M, Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope116(3), 407–412 (2006).
   PubMed Web of Science ®Google Scholar
• Hotomi M, Ikeda Y, Suzumoto M et al. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine23(10), 1294–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Kodama S, Hirano T, Abe N, Suzuki M. Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae -specific mucosal IgA responses in the middle ear. Acta Otolaryngol.127(8), 809–815 (2007).
   PubMed Web of Science ®Google Scholar
• Mason KW, Zhu D, Scheuer CA et al. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Vaccine22(25–26), 3449–3456 (2004).
   PubMed Web of Science ®Google Scholar
• Jiao X, Hirano T, Hou Y, Gu XX. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect. Immun.70(11), 5982–5989 (2002).
   PubMed Web of Science ®Google Scholar
• Clancy RL, Cripps AW, Husband AJ, Buckley D. Specific immune response in the respiratory tract after administration of an oral polyvalent bacterial vaccine. Infect. Immun.39(2), 491–496 (1983).
   PubMed Web of Science ®Google Scholar
• Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Aust. NZ J. Med.21(4), 427–432 (1991).
   PubMedGoogle Scholar
• Steurer-Stey C, Lagler L, Straub DA, Steurer J, Bachmann LM. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur. J. Pediatr.166(4), 365–376 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis . Vaccine24(26), 5420–5425 (2006).
   PubMed Web of Science ®Google Scholar
• Shoemaker DR, Saunders NB, Brandt BL et al. Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits. Infect. Immun.73(8), 5031–5038 (2005).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103(29), 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar
• Bowe F, Lavelle EC, McNeela EA et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun.72(7), 4052–4060 (2004).
   PubMed Web of Science ®Google Scholar
• Huo Z, Sinha R, McNeela EA et al. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect. Immun.73(12), 8256–8265 (2005).
   PubMed Web of Science ®Google Scholar
• Alonso S, Willery E, Renauld-Mongenie G, Locht C. Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier. Infect. Immun.73(7), 4295–4301 (2005).
   PubMed Web of Science ®Google Scholar
• Lee SF, Halperin SA, Salloum DF, MacMillan A, Morris A. Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect. Immun.71(4), 2272–2275 (2003).
   PubMed Web of Science ®Google Scholar
• Hale C, Humphreys IR, Hussell T et al. Mucosal immunisation of murine neonates using whole cell and acellular pertussis vaccines. Vaccine22(27–28), 3595–3602 (2004).
   PubMed Web of Science ®Google Scholar
• Berstad AK, Holst J, Froholm LO et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol.49(2), 157–163 (2000).
   PubMed Web of Science ®Google Scholar
• Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect. Immun.71(3), 1453–1461 (2003).
   PubMed Web of Science ®Google Scholar
• Gocke K, Baumann U, Hagemann H et al. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol. Med. Microbiol.37(2–3), 167–171 (2003).
   PubMedGoogle Scholar
• Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol.26(12), 660–667 (2005).
   PubMed Web of Science ®Google Scholar
• Tjarnlund A, Rodriguez A, Cardona PJ et al. Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice. Int. Immunol.18(5), 807–816 (2006).
   PubMed Web of Science ®Google Scholar
• Hamasur B, Haile M, Pawlowski A et al. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab´) fragment prolong survival of mice infected with Mycobacterium tuberculosis . Clin. Exp. Immunol.138(1), 30–38 (2004).
   PubMed Web of Science ®Google Scholar
• Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb.)87(4), 257–266 (2007).
   PubMed Web of Science ®Google Scholar
• Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared with subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun.72(1), 238–246 (2004).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sasaki K, Takahashi M et al. Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus Calmette–Guerin in mice. Vaccine24(17), 3591–3598 (2006).
   PubMed Web of Science ®Google Scholar
• Haile M, Hamasur B, Jaxmar T et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinb.)85(1–2), 107–114 (2005).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74(8), 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guerin immunity. J. Immunol.177(9), 6353–6360 (2006).
   PubMed Web of Science ®Google Scholar
• Rudin A, Riise GC, Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect. Immun.67(6), 2884–2890 (1999).
   PubMed Web of Science ®Google Scholar
• Ebensen T, Schulze K, Riese P, Morr M, Guzman CA. The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin. Vaccine Immunol.14(8), 952–958 (2007).
   PubMed Web of Science ®Google Scholar
• Hall MA, Stroop SD, Hu MC et al. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun.72(5), 2507–2512 (2004).
   PubMed Web of Science ®Google Scholar
• Becker PD, Bertot GM, Souss D et al. Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect. Immun.75(4), 1778–1784 (2007).
   PubMed Web of Science ®Google Scholar
• Ebensen T, Link C, Riese P et al. A pegylated derivative of α-galactosylceramide exhibits improved biological properties. J. Immunol.179(4), 2065–2073 (2007).
   PubMed Web of Science ®Google Scholar
• Ebensen T, Schulze K, Riese P et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine25(8), 1464–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Link C, Gavioli R, Ebensen T et al. The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur. J. Immunol.34(3), 899–907 (2004).
   PubMed Web of Science ®Google Scholar
• Larbig M, Mansouri E, Freihorst J et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine19(17–19), 2291–2297 (2001).
   PubMed Web of Science ®Google Scholar
• Audouy SA, van Roosmalen ML, Neef J et al.Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine24(26), 5434–5441 (2006).
   PubMed Web of Science ®Google Scholar
• Malley R, Lipsitch M, Stack A et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect. Immun.69(8), 4870–4873 (2001).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Dietrich J, Agger EM et al. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis . Infect. Immun.75(1), 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Nawar HF, Arce S, Russell MW, Connell TD. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect. Immun.75(2), 621–633 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun.71(8), 4780–4788 (2003).
   PubMed Web of Science ®Google Scholar
• Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173(10), 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Audouy SA, van Selm S, van Roosmalen ML et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine25(13), 2497–2506 (2007).
   PubMed Web of Science ®Google Scholar
• Briles DE, Ades E, Paton JC et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae . Infect. Immun.68(2), 796–800 (2000).
   PubMed Web of Science ®Google Scholar
• Areas AP, Oliveira ML, Miyaji EN et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli : ability of CTB-PsaA to induce humoral immune response in mice. Biochem. Biophys. Res. Commun.321(1), 192–196 (2004).
   PubMed Web of Science ®Google Scholar
• Pimenta FC, Miyaji EN, Areas AP et al. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice. Infect. Immun.74(8), 4939–4944 (2006).
   PubMed Web of Science ®Google Scholar
• Seo JY, Seong SY, Ahn BY et al. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect. Immun.70(3), 1143–1149 (2002).
   PubMed Web of Science ®Google Scholar
• Baudner BC, Balland O, Giuliani MM et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun.70(9), 4785–4790 (2002).
   PubMed Web of Science ®Google Scholar
• Isaka M, Komiya T, Takahashi M et al. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria–pertussis–tetanus (DPT) combination vaccine. Vaccine22(23–24), 3061–3068 (2004).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine16(20), 2039–2046 (1998).
   PubMed Web of Science ®Google Scholar
• Walker MJ, Rohde M, Timmis KN, Guzman CA. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit. Infect. Immun.60(10), 4260–4268 (1992).
   PubMed Web of Science ®Google Scholar
• Zuercher AW, Horn MP, Que JU et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol.47(2), 302–308 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas LD, Kyd JM, Bastin DA, Dunkley ML, Cripps AW. Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa . FEMS Immunol. Med. Microbiol.37(2–3), 155–160 (2003).
   PubMed Web of Science ®Google Scholar
• Buret A, Dunkley ML, Pang G, Clancy RL, Cripps AW. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor a, and interleukin-1 α. Infect. Immun.62(12), 5335–5343 (1994).
   PubMed Web of Science ®Google Scholar
• Abraham E. Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine10(7), 461–468 (1992).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol.80(10), 4962–4970 (2006).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Smith B, Clarke K et al. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Hum. Vaccin.1(1), 37–42 (2005).
   PubMed Web of Science ®Google Scholar
• Langley JM, Halperin SA, McNeil S et al. Safety and immunogenicity of a proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine24(10), 1601–1608 (2006).
   PubMed Web of Science ®Google Scholar
• Treanor J, Nolan C, O’Brien D et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine24(3), 254–262 (2006).
   PubMed Web of Science ®Google Scholar
• Fries LF, Montemarano AD, Mallett CP et al. Safety and immunogenicity of a proteosome- Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun.69(7), 4545–4553 (2001).
   PubMed Web of Science ®Google Scholar
• Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine23(8), 1029–1036 (2005).
   PubMed Web of Science ®Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine22(8), 909–914 (2004).
   PubMed Web of Science ®Google Scholar